Pamrevlumab (FG-3019): A Comprehensive Monograph on a First-in-Class CTGF Inhibitor from Clinical Promise to Program Termination

1.0 Executive Summary

Pamrevlumab (development code: FG-3019) was an investigational, first-in-class, fully human monoclonal antibody developed by FibroGen, Inc., designed to inhibit the activity of Connective Tissue Growth Factor (CTGF). CTGF is a central mediator in the pathophysiology of numerous fibrotic and proliferative disorders, making it a highly attractive therapeutic target. The development of Pamrevlumab was predicated on the ambitious hypothesis that inhibiting this single molecular hub could yield disease-modifying effects across a range of distinct and complex conditions, including idiopathic pulmonary fibrosis (IPF), Duchenne muscular dystrophy (DMD), and pancreatic cancer.

The drug's early and mid-stage clinical development was marked by considerable promise. Phase 2 studies, particularly in IPF, suggested that Pamrevlumab could significantly slow disease progression, a finding that, combined with a consistently favorable safety and tolerability profile, garnered multiple special regulatory designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including Fast Track, Orphan Drug, and Rare Pediatric Disease designations across its target indications. This initial success supported the launch of a large, parallel, and costly late-stage clinical program, with pivotal Phase 3 trials initiated simultaneously for IPF, DMD, and pancreatic cancer.

However, this promising trajectory ended in a cascade of definitive clinical failures. Between June 2023 and July 2024, every one of Pamrevlumab's pivotal Phase 3 trials failed to meet its primary efficacy endpoint. The ZEPHYRUS-1 trial in IPF, the LELANTOS-1 and LELANTOS-2 trials in DMD, and the LAPIS and Precision Promise trials in pancreatic cancer all demonstrated no statistically significant benefit over placebo or standard of care. This stark and consistent disconnect between the encouraging signals from Phase 2 studies and the negative outcomes of large, well-controlled Phase 3 trials underscores the peril of over-relying on surrogate endpoints and less rigorous trial designs in mid-stage development.

The failure was not attributable to safety concerns; Pamrevlumab was generally well-tolerated throughout its development, even when combined with aggressive chemotherapy. Instead, the complete lack of efficacy across three different disease states strongly suggests a fundamental flaw in the core therapeutic hypothesis: that inhibiting CTGF alone is insufficient to meaningfully alter the course of these complex, multifactorial diseases. Following the final trial failures in pancreatic cancer, FibroGen announced the complete termination of the Pamrevlumab research and development program. The story of Pamrevlumab serves as a significant and cautionary case study in modern drug development, illustrating the immense challenges of translating a compelling biological rationale into clinical success and the systemic risks of a "pipeline-in-a-product" strategy when predicated on a single, unproven mechanism of action.

2.0 Molecular Profile and Pharmacological Basis

Pamrevlumab represents a targeted biological therapy developed to intercept a key pathway implicated in a variety of pathological conditions characterized by excessive tissue remodeling and cellular proliferation. Its identity as a first-in-class agent is defined by its unique molecular target and its nature as a precisely engineered human monoclonal antibody.

2.1 Drug Identification and Physicochemical Properties

Pamrevlumab is a biotech therapeutic classified as a fully human recombinant monoclonal antibody.[1] It was engineered to provide high specificity for its target with a structure intended to minimize immunogenicity in human subjects. The key identifiers and properties of the molecule are summarized in Table 1.

Table 1: Key Properties of Pamrevlumab

Property	Description	Source(s)
International Nonproprietary Name (INN)	Pamrevlumab	3
Development Code	FG-3019	3
Synonyms	Anti-CTGF antibody, Anti-connective tissue growth factor monoclonal antibody FG-3019	4
DrugBank ID	DB14952	[User Query]
CAS Number	946415-13-0	3
UNII	QS5F6VTS0O	3
Developer	FibroGen, Inc.	2
Molecular Formula	C6492​H10018​N1718​O2086​S48​	3
Molar Mass	Approximately 147,050.38 g·mol⁻¹ (147.1 kDa)	3
Antibody Isotype	Human Immunoglobulin G1, kappa light chain (IgG1, κ)	6
Target	Connective Tissue Growth Factor (CTGF / CCN2)	3
Mechanism of Action	CTGF Inhibitor	4
Formulation	Solution for intravenous (IV) infusion in Phosphate-Buffered Saline (PBS), pH 7.4	6

Pamrevlumab is a large protein therapeutic with a molecular weight of approximately 147 kDa.[3] As a human IgG1 kappa monoclonal antibody, its structure is composed of two identical heavy chains and two identical kappa light chains, forming a "Y" shape characteristic of this immunoglobulin class.[6] This structure was selected to leverage the long half-life and effector functions associated with the IgG1 isotype, while its fully human sequence was designed to reduce the risk of generating anti-drug antibodies.[2] For clinical use, it was formulated as a sterile, colorless to light yellow liquid solution for intravenous administration.[7]

2.2 Mechanism of Action: Targeting Connective Tissue Growth Factor (CTGF)

The entire therapeutic rationale for Pamrevlumab was built upon the inhibition of its specific molecular target, Connective Tissue Growth Factor (CTGF), a protein identified as a central node in pathological processes of fibrosis and cancer progression.

2.2.1 The Central Role of CTGF in Disease Pathophysiology

Connective Tissue Growth Factor, also known as CCN family member 2 (CCN2) or Insulin-like growth factor-binding protein 8 (IGFBP-8), is a 36-38 kDa, cysteine-rich secreted glycoprotein.[2] Under normal physiological conditions, CTGF is involved in processes like wound healing and tissue repair. However, its overexpression is a hallmark of numerous pathological states.[5] CTGF functions as a critical downstream mediator of Transforming Growth Factor-beta (TGF-β), a master regulator of fibrosis.[2] The synergy between TGF-β and CTGF creates a potent positive feedback loop that amplifies the fibrotic cascade, leading to the excessive deposition of extracellular matrix (ECM) components such as collagen and fibronectin, and the activation of myofibroblasts—the primary cells responsible for scar tissue formation.[5]

Beyond its role in fibrosis, CTGF is a multifunctional signaling modulator involved in cell proliferation, migration, adhesion, and angiogenesis.[2] It exerts these effects by interacting with various cell surface receptors, including integrins and heparan sulfate proteoglycans.[2] The specific integrin receptor utilized by CTGF varies by cell type (e.g., integrin

αv​β3​ in endothelial cells, integrin α6​β1​ in skin fibroblasts), allowing it to influence a wide array of cellular behaviors.[2] Furthermore, CTGF is highly expressed in the tumor microenvironment of desmoplastic cancers, such as pancreatic cancer, where it promotes stromal cell proliferation, tumor growth, and resistance to therapy.[5] Its expression has been documented in at least 21 different human tumor types, highlighting its broad importance in oncology.[2]

2.2.2 Pamrevlumab's Inhibitory Action and the "Central Hub" Hypothesis

Pamrevlumab was designed as a high-affinity antagonist of CTGF.[5] As a monoclonal antibody, it binds specifically to CTGF, thereby physically blocking the growth factor from interacting with its cell surface receptors.[5] This direct inhibition of the ligand-receptor interaction is the fundamental mechanism by which Pamrevlumab was expected to exert its therapeutic effects. By neutralizing CTGF, the antibody was hypothesized to disrupt the downstream signaling cascades that drive fibrosis and tumor progression. The anticipated outcomes included a reduction in ECM production, decreased myofibroblast activation, suppression of tumor cell proliferation, and ultimately, the potential to halt or even reverse tissue scarring.[5]

The decision by FibroGen to pursue clinical development in such disparate diseases as IPF (an idiopathic fibrotic lung disease), DMD (a genetic neuromuscular disorder with a fibrotic component), and pancreatic cancer (a desmoplastic malignancy) was rooted in a compelling but highly ambitious therapeutic hypothesis. This "central hub" hypothesis posited that because CTGF is a common, critical convergence point for pathological signaling in all these conditions, inhibiting this single target could be a viable, disease-modifying strategy across the board.[15] This approach suggested that Pamrevlumab could function as a "pipeline-in-a-product," with the potential for multiple high-value indications. However, this strategy also carried a significant, correlated risk: if the central hypothesis was flawed—if CTGF was not as critical or its inhibition was insufficient to overcome redundant pathological pathways—then the entire multi-billion dollar development program was vulnerable to systemic failure. The ultimate clinical outcomes for Pamrevlumab would serve as a definitive test of this foundational scientific premise.

3.0 Clinical Development in Fibrotic and Proliferative Disorders

The clinical development of Pamrevlumab was extensive and ambitious, spanning multiple therapeutic areas and progressing to late-stage trials in three major indications. The program's trajectory was characterized by highly encouraging mid-stage results that ultimately failed to translate into success in large, confirmatory Phase 3 studies. A summary of the major clinical trials is provided in Table 2.

Table 2: Summary of Major Pamrevlumab Clinical Trials

Trial Acronym/ID	NCT ID	Indication	Phase	Patient Population	Primary Endpoint	Outcome Summary
PRAISE	NCT01890265	Idiopathic Pulmonary Fibrosis (IPF)	2	Patients with IPF	Change in FVC % predicted at Week 48	Positive: Met primary endpoint, significantly reduced FVC decline vs. placebo.11
ZEPHYRUS-1	NCT03955146	Idiopathic Pulmonary Fibrosis (IPF)	3	Patients with IPF	Change in FVC from baseline at Week 48	Negative: Failed to meet primary endpoint; no significant difference vs. placebo.17
ZEPHYRUS-2	NCT04419558	Idiopathic Pulmonary Fibrosis (IPF)	3	Patients with IPF	Change in FVC from baseline at Week 48	Terminated: Discontinued following the failure of ZEPHYRUS-1.4
MISSION	NCT02606136	Duchenne Muscular Dystrophy (DMD)	2	Non-ambulatory patients with DMD	Change in ppFVC at 2 years	Encouraging: Showed slower decline in pulmonary function vs. historical controls.18
LELANTOS-1	NCT04371666	Duchenne Muscular Dystrophy (DMD)	3	Non-ambulatory patients with DMD	Change in Performance of Upper Limb (PUL) 2.0 score	Negative: Failed to meet primary endpoint.4
LELANTOS-2	NCT04632940	Duchenne Muscular Dystrophy (DMD)	3	Ambulatory patients with DMD	Change in North Star Ambulatory Assessment (NSAA) score	Negative: Failed to meet primary and secondary endpoints.19
LAPIS	NCT03941093	Locally Advanced Pancreatic Cancer (LAPC)	3	Patients with unresectable LAPC	Overall Survival (OS)	Negative: Failed to meet primary endpoint of improving OS vs. standard of care.20
Precision Promise	NCT04229004	Metastatic Pancreatic Cancer	2/3	Patients with metastatic PDAC	Overall Survival (OS)	Negative: Failed to meet primary endpoint of improving OS vs. standard of care.20
NCT00754143	NCT00754143	Diabetic Nephropathy	1	Patients with Type 1/2 Diabetes and diabetic nephropathy	Safety and PK	Encouraging: Well-tolerated; associated with a decrease in albuminuria.21

3.1 Idiopathic Pulmonary Fibrosis (IPF)

The development program in IPF was initially the most promising for Pamrevlumab, built on a strong Phase 2 result that generated significant optimism for a new therapeutic class in a disease with high unmet need.

3.1.1 The Promise of Phase 2 (PRAISE Trial)

The foundation of the IPF program was the Phase 2 PRAISE trial (NCT01890265), a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of Pamrevlumab (30 mg/kg IV every 3 weeks) over 48 weeks.[11] The results, published in

The Lancet Respiratory Medicine, were highly positive and suggested a substantial treatment effect.[11] The study successfully met its primary efficacy endpoint, demonstrating that Pamrevlumab significantly attenuated the decline in lung function. The mean change from baseline in percentage of predicted Forced Vital Capacity (FVC) at week 48 was -2.9% in the Pamrevlumab group compared to -7.2% in the placebo group, representing a 60.3% relative reduction in FVC decline (between-group difference 4.3%; p=0.033).[11]

Furthermore, Pamrevlumab met a key secondary endpoint of disease progression, defined as a decline from baseline in FVC of ≥10% or death. At week 48, only 10.0% of patients in the Pamrevlumab group experienced disease progression, compared to 31.4% in the placebo group (p=0.013).[11] The drug was also well-tolerated, with a safety profile similar to placebo.[11] These robust and statistically significant results were a major success, positioning Pamrevlumab as one of the most promising investigational therapies for IPF and providing a strong rationale for advancing into a pivotal Phase 3 program.[11]

3.1.2 The Failure of Phase 3 (ZEPHYRUS-1 Trial)

To confirm the promising Phase 2 findings, FibroGen launched a large Phase 3 program consisting of two identical trials, ZEPHYRUS-1 (NCT03955146) and ZEPHYRUS-2.[24] ZEPHYRUS-1 enrolled 356 patients with IPF who were randomized to receive either Pamrevlumab or placebo for 48 weeks.[25] The primary endpoint was the absolute change in FVC from baseline, the same key measure used in the successful PRAISE trial.[25]

In a major setback for the program, FibroGen announced in June 2023 that the ZEPHYRUS-1 trial had failed to meet its primary endpoint.[17] The mean decline in FVC from baseline to week 48 was 260 mL in the Pamrevlumab arm and 330 mL in the placebo arm.[17] The resulting 70 mL difference between the groups was not statistically significant (95% CI -60 to 190 mL; p=0.29).[17] The study also failed to meet its key secondary endpoints, including time to disease progression (HR= 0.78; 95% CI 0.52 to 1.15).[17]

3.1.3 Program Discontinuation

The definitive negative result from ZEPHYRUS-1 was irreconcilable with the earlier Phase 2 data and removed any viable path forward for Pamrevlumab in IPF. Consequently, FibroGen immediately announced the discontinuation of the second confirmatory Phase 3 trial, ZEPHYRUS-2 (NCT04419558), effectively terminating the IPF development program.[4] This failure marked the first of three major late-stage disappointments for Pamrevlumab and raised significant questions about the drug's underlying mechanism and the reproducibility of its earlier clinical signals.

3.2 Duchenne Muscular Dystrophy (DMD)

The rationale for investigating Pamrevlumab in DMD stemmed from the central role of fibrosis in the disease's pathology. In DMD, the absence of functional dystrophin leads to chronic muscle damage, inflammation, and the progressive replacement of muscle tissue with non-functional fibrotic scar tissue, which contributes significantly to muscle weakness and loss of function.[16] By inhibiting CTGF, Pamrevlumab was hypothesized to be a mutation-agnostic, anti-fibrotic therapy that could preserve muscle function.[29]

3.2.1 Rationale and Early Data

The DMD program was initiated based on encouraging preclinical data and was advanced with the Phase 2 MISSION trial (NCT02606136).[18] This was an open-label, single-arm study that enrolled 21 non-ambulatory patients with DMD, a population with high unmet need.[16] The results, published in the

Journal of Neuromuscular Diseases, showed that after two years of treatment, the annual rate of decline in percent predicted FVC (a measure of pulmonary function) was slower than that observed in historical control cohorts of non-ambulatory patients.[18] Patients also experienced slower-than-anticipated declines in upper limb muscle function.[18] While limited by its open-label design and reliance on historical comparisons, the study demonstrated that Pamrevlumab was well-tolerated and provided a sufficient signal of potential efficacy to justify a large-scale Phase 3 program.[18]

3.2.2 Late-Stage Failures (LELANTOS-1 & LELANTOS-2)

FibroGen launched two pivotal, randomized, double-blind, placebo-controlled Phase 3 trials to evaluate Pamrevlumab in both non-ambulatory and ambulatory DMD populations. LELANTOS-1 (NCT04371666) enrolled non-ambulatory patients, while LELANTOS-2 (NCT04632940) enrolled ambulatory boys aged 6 to 12.[4]

Both trials failed. In August 2023, FibroGen announced that the LELANTOS-2 trial in ambulatory patients did not meet its primary endpoint, which was the change from baseline in the North Star Ambulatory Assessment (NSAA) total score, a key measure of functional motor abilities.[19] The trial also failed to meet its key secondary endpoints, including the four-stair climb velocity and the 10-meter walk/run test.[19] This news followed the earlier failure of the LELANTOS-1 trial in the non-ambulatory population.[4] The consecutive failures in two well-controlled Phase 3 studies definitively demonstrated a lack of clinical benefit and led to the termination of the DMD program, marking the second major indication failure for Pamrevlumab.[19]

3.3 Pancreatic Cancer

The therapeutic hypothesis for Pamrevlumab in pancreatic cancer focused on targeting the dense, fibrotic tumor stroma, or microenvironment, which is a hallmark of pancreatic ductal adenocarcinoma (PDAC).[13] CTGF is highly overexpressed in this stroma and is believed to promote tumor growth, shield cancer cells from chemotherapy, and prevent immune infiltration.[13] The strategy was to combine Pamrevlumab with standard-of-care chemotherapy to disrupt the protective stroma and enhance the efficacy of cytotoxic agents.[13]

3.3.1 Rationale and Early Promise

Early-phase clinical data provided encouraging signs that this strategy might be effective. A Phase 2 study in patients with locally advanced, unresectable pancreatic cancer (LAPC) suggested that adding Pamrevlumab to gemcitabine and nab-paclitaxel chemotherapy increased the proportion of patients whose tumors became amenable to surgical resection—a potentially curative intervention.[13] In the study, 7 of 12 patients treated with the Pamrevlumab combination became eligible for surgery, compared to only 1 of 11 treated with chemotherapy alone.[13] These promising results, suggesting a meaningful clinical benefit in a disease with a grim prognosis, were the basis for the FDA granting Fast Track designation and supported the decision to proceed to late-stage trials.[33]

3.3.2 Definitive Phase 3 Failures (LAPIS & Precision Promise)

Two large, late-stage trials were conducted to validate the early signals. The LAPIS study (NCT03941093) was a global, randomized, double-blind, placebo-controlled Phase 3 trial in 284 patients with LAPC.[20] Concurrently, Pamrevlumab was evaluated in patients with metastatic PDAC as an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) innovative Precision Promise Phase 2/3 adaptive platform trial (NCT04229004).[20]

In July 2024, FibroGen announced that both trials had failed.[20] The primary endpoint for both studies was overall survival (OS), the gold standard for efficacy in oncology. In the LAPIS trial, the addition of Pamrevlumab to standard chemotherapy did not improve OS; the median OS was 17.3 months in the Pamrevlumab arm versus 17.9 months in the control arm (HR: 1.08; 95% CI – 0.83 to 1.41).[20] Similarly, the Pamrevlumab arm of the Precision Promise trial failed to demonstrate an OS benefit compared to standard chemotherapy in patients with metastatic disease.[20]

3.3.3 Termination of the Entire Program

The dual failures in pancreatic cancer represented the third and final major setback for Pamrevlumab. Having now failed to demonstrate efficacy in three distinct, well-powered, late-stage programs, the evidence against the drug's clinical utility was overwhelming. In response to the pancreatic cancer data, FibroGen announced the immediate and complete termination of all remaining research and development activities for Pamrevlumab, accompanied by a significant corporate restructuring to reduce costs.[20]

The consistent pattern of promising Phase 2 data followed by definitive Phase 3 failure across IPF, DMD, and pancreatic cancer points to a critical lesson in drug development. Early signals of efficacy, particularly when based on surrogate endpoints (FVC in IPF, resection rate in pancreatic cancer) or less rigorous trial designs (open-label, historical controls in DMD), may not be reliable predictors of success in large, randomized, placebo-controlled trials designed to measure hard clinical outcomes like survival or functional improvement. This repeated disconnect suggests that the initial positive results were likely either statistical anomalies or that the observed effects on surrogate markers did not translate into meaningful, tangible benefits for patients. This history serves as a powerful cautionary example of the risks of building a major late-stage development program on mid-stage data that has not yet been rigorously validated.

3.4 Exploratory Indications

Reflecting the broad potential envisioned by the "central hub" hypothesis, Pamrevlumab was also evaluated in several other conditions in early-phase clinical trials. While none of these programs advanced to late-stage development, they further illustrate the scope of the initial scientific rationale.

• Diabetic Nephropathy and Diabetes Mellitus: A completed Phase 1 open-label, dose-escalation trial (NCT00754143) in 24 patients with type 1 or type 2 diabetes and microalbuminuria found that Pamrevlumab was well-tolerated.[21] Notably, the study reported a statistically significant decrease in the urinary albumin/creatinine ratio (ACR), a key marker of kidney damage, suggesting a potential therapeutic effect.[22]
• Focal Segmental Glomerulosclerosis (FSGS): A Phase 1 safety and pharmacokinetic study (NCT00782561) in adolescents and adults with FSGS was initiated but was ultimately terminated before completion.[38]
• COVID-19: During the global pandemic, a Phase 2 randomized, placebo-controlled trial (NCT04432298) was initiated to evaluate Pamrevlumab in hospitalized patients with acute COVID-19, presumably to target the fibrotic lung damage associated with severe disease.[4] This trial was also terminated prematurely.[4]

4.0 Clinical Pharmacology: Safety, Tolerability, and Pharmacokinetics

A comprehensive assessment of Pamrevlumab's clinical pharmacology reveals a notable dichotomy: a consistently favorable and benign safety profile stands in stark contrast to its ultimate lack of efficacy. The pharmacokinetic data, while limited, provides insight into the drug's disposition and target engagement.

4.1 Safety and Tolerability Profile

Across more than a decade of clinical investigation in diverse patient populations and disease states, Pamrevlumab consistently demonstrated that it was a safe and well-tolerated agent.[2] This benign safety profile was a key feature highlighted throughout its development and was confirmed even in the large, failed Phase 3 trials.

4.1.1 Safety in Idiopathic Pulmonary Fibrosis (IPF)

In the Phase 2 PRAISE trial, Pamrevlumab's safety profile was similar to that of placebo.[11] As detailed in Table 3, the overall incidence of adverse events was nearly identical between the groups. While treatment-emergent serious adverse events (SAEs) were numerically higher in the Pamrevlumab group (24%) compared to the placebo group (15%), this difference was not statistically significant, and none of the deaths that occurred during the trial were considered treatment-related by investigators.[11]

Table 3: Summary of Adverse Events in the Phase 2 PRAISE Trial (IPF)

Category of Adverse Event	Pamrevlumab (n=50)	Placebo (n=53)
Any adverse event	48 (96%)	52 (98%)
Serious adverse events	12 (24%)	8 (15%)
All reported deaths	3 (6%)	6 (11%)
Adverse events leading to discontinuation	10 (20%)	10 (19%)
Most frequent adverse events (>10% incidence)
Cough	14 (28%)	23 (43%)
Dyspnoea	14 (28%)	11 (21%)
Respiratory tract infection	15 (30%)	11 (21%)
Idiopathic pulmonary fibrosis (exacerbation)	10 (20%)	9 (17%)
Fatigue	10 (20%)	4 (8%)
Urinary tract infection	10 (20%)	4 (8%)
Source: Adapted from Richeldi L, et al. The Lancet Respiratory Medicine. 2020. 11

This favorable safety profile was robustly confirmed in the much larger Phase 3 ZEPHYRUS-1 trial, as shown in Table 4. In this study involving 356 patients, the incidence of SAEs was actually lower in the Pamrevlumab group (28.2%) than in the placebo group (34.3%).[17] The number of deaths was identical in both arms (23 patients, or ~13%).[27] The consistency of these safety data across both Phase 2 and Phase 3 trials strongly indicates that the drug itself did not introduce significant toxicity.

Table 4: Summary of Adverse Events in the Phase 3 ZEPHYRUS-1 Trial (IPF)

Category of Adverse Event	Pamrevlumab (n=181)	Placebo (n=175)
Any treatment-related adverse event	160 (88.4%)	151 (86.3%)
Serious adverse events	51 (28.2%)	60 (34.3%)
Deaths during the study	23 (12.7%)	23 (13.1%)
Source: Adapted from Raghu G, et al. JAMA. 2024. 27

4.1.2 Safety in Other Indications

The benign safety profile of Pamrevlumab was also observed in its other development programs:

• Duchenne Muscular Dystrophy (DMD): In the Phase 2 MISSION trial, treatment-emergent adverse events were reported as being mild to moderate in severity, and importantly, none led to discontinuation of the study drug.[18] The subsequent Phase 3 LELANTOS-2 trial also reported that adverse effects were primarily mild to moderate.[19]
• Pancreatic Cancer: The most rigorous test of Pamrevlumab's safety was in combination with highly toxic chemotherapy regimens. Preliminary safety analyses from both the LAPIS and Precision Promise trials concluded that the addition of Pamrevlumab to either gemcitabine + nab-paclitaxel or FOLFIRINOX was generally well-tolerated.[20] Crucially, there were no clinically meaningful differences in treatment-emergent adverse events between the Pamrevlumab-containing arms and the chemotherapy-alone control arms.[20]

The overall safety data across the entire program is a critical piece of evidence in the analysis of Pamrevlumab's failure. It strongly refutes the possibility that the drug was terminated due to safety or tolerability issues. Instead, it isolates the lack of efficacy as the sole reason for the program's demise, reinforcing the conclusion that the fundamental therapeutic hypothesis—that inhibiting CTGF could modify these diseases—was incorrect.

4.2 Pharmacokinetics and Pharmacodynamics (PK/PD)

Publicly available information on the full absorption, distribution, metabolism, and excretion (ADME) profile of Pamrevlumab is limited, with databases like DrugBank noting that these data are not available.[40] However, insights can be gleaned from early clinical trial publications and pharmacokinetic modeling analyses.

4.2.1 Pharmacokinetics

The first human pharmacokinetic data for Pamrevlumab came from the Phase 1 trial in patients with diabetic kidney disease (NCT00754143).[22] This study revealed that Pamrevlumab exhibits non-linear pharmacokinetics. Specifically, drug clearance was found to be lower at a higher dose (10 mg/kg) compared to a lower dose (3 mg/kg).[22] This dose-dependent change in clearance is characteristic of target-mediated drug disposition (TMDD).[41] TMDD occurs when a significant fraction of a drug is eliminated through binding to its pharmacological target. At lower doses, this high-affinity binding represents a major route of clearance, but as the dose increases and the target becomes saturated, the clearance pathway also becomes saturated, leading to disproportionately higher drug exposure and a longer half-life.[22] This finding confirmed that Pamrevlumab was engaging its CTGF target with high affinity in vivo.

Pharmacokinetic and pharmacodynamic (PK/PD) modeling was later used to optimize the dosing regimen for the Phase 3 programs. An analysis presented by FibroGen based on data from the Phase 2 PRAISE trial predicted that a dose of 30 mg/kg administered intravenously every 3 weeks would have a greater than 90% probability of achieving superiority over placebo in slowing FVC decline in IPF.[42] This prediction, while based on sound modeling principles, ultimately proved to be incorrect when tested in the ZEPHYRUS-1 trial, highlighting the inherent uncertainties in extrapolating from mid-stage PK/PD models to late-stage clinical efficacy outcomes.

4.2.2 Pharmacodynamics

Pharmacodynamic assessments confirmed that Pamrevlumab engaged its target and modulated its biology. The Phase 1 study in diabetic kidney disease measured plasma levels of the N-terminal fragment of CTGF.[22] Following Pamrevlumab infusion, levels of this fragment increased significantly, which was interpreted as a reflection of the antibody binding to full-length CTGF and altering its subsequent processing and clearance.[22] This provided direct evidence of target engagement in humans. This pharmacodynamic effect was observed concurrently with a therapeutic signal (a reduction in albuminuria), suggesting a link between target engagement and biological activity in this early study.[37]

4.3 Drug-Drug Interactions

Formal drug-drug interaction studies for Pamrevlumab are not extensively reported in the public domain. The information available, primarily from databases such as DrugBank, consists largely of theoretical or class-based potential interactions.[40]

• Interactions with Other Monoclonal Antibodies: A general precaution is noted for the co-administration of Pamrevlumab with a wide variety of other therapeutic monoclonal antibodies (e.g., amivantamab, avelumab, benralizumab, daratumumab, durvalumab).[40] The basis for this warning is a potential for an increased risk or severity of adverse effects, a general pharmacodynamic concern when combining potent biologics that may have overlapping effects on the immune system or other physiological processes.[40]
• Interactions with Hormonal Agents: A potential pharmacodynamic interaction is listed with estrogenic compounds, including conjugated estrogens, estradiol, and ethinylestradiol.[40] It is suggested that these agents may increase the thrombogenic activities of Pamrevlumab.[40] The clinical relevance and mechanistic basis of this potential interaction have not been established.

In clinical practice, the most relevant interaction data comes from the IPF and pancreatic cancer trials. In the PRAISE sub-study and the ZEPHYRUS trials, Pamrevlumab was administered with or without the approved IPF therapies pirfenidone and nintedanib, and no new safety signals were identified, suggesting it could be safely co-administered.[43] Similarly, in the pancreatic cancer trials, Pamrevlumab was well-tolerated in combination with gemcitabine, nab-paclitaxel, and FOLFIRINOX, indicating a lack of significant synergistic toxicity.[20]

5.0 Regulatory Trajectory and Strategic Milestones

The regulatory history of Pamrevlumab is a story of two distinct phases: an initial period of significant positive engagement and encouragement from regulatory bodies, evidenced by numerous special designations, followed by a final phase of withdrawal and termination after the clinical data failed to support its initial promise. FibroGen's strategic approach was to leverage this early regulatory support to drive an aggressive, parallel development program.

Table 5: Timeline of Key Regulatory Designations (FDA & EMA)

Date	Regulatory Agency	Designation Type	Indication	Status
Oct 2017	U.S. FDA	Orphan Drug Designation	Pancreatic Cancer	Granted 14
Mar 2018	U.S. FDA	Fast Track Designation	Locally Advanced Unresectable Pancreatic Cancer	Granted 33
Sep 2018	U.S. FDA	Fast Track Designation	Idiopathic Pulmonary Fibrosis (IPF)	Granted 2
Apr 2019	U.S. FDA	Orphan Drug Designation	Duchenne Muscular Dystrophy (DMD)	Granted 46
Dec 2019	EMA	Orphan Designation (EU/3/19/2234)	Duchenne Muscular Dystrophy (DMD)	Granted 48
Apr 2021	U.S. FDA	Fast Track Designation	Duchenne Muscular Dystrophy (DMD)	Granted 29
(Undated)	U.S. FDA	Orphan Drug Designation	Idiopathic Pulmonary Fibrosis (IPF)	Granted 47
(Undated)	U.S. FDA	Rare Pediatric Disease Designation	Duchenne Muscular Dystrophy (DMD)	Granted 17
Oct 2024	EMA	Orphan Designation (EU/3/19/2234)	Duchenne Muscular Dystrophy (DMD)	Withdrawn 48

5.1 U.S. Food and Drug Administration (FDA) Engagement

Pamrevlumab's journey with the FDA was characterized by substantial early support, reflecting the agency's recognition of the high unmet medical needs in the targeted diseases and the strength of the initial clinical data. The drug accumulated an impressive array of special designations designed to expedite the development and review of promising new therapies.[53]

• Fast Track Designation: Pamrevlumab received Fast Track designation for all three of its major indications: LAPC in March 2018, IPF in September 2018, and DMD in April 2021.[33] This status is granted to drugs that treat serious conditions and fill an unmet medical need, and it allows for more frequent communication with the FDA to resolve issues quickly and potentially shorten the review timeline.[34]
• Orphan Drug Designation: The FDA also granted Orphan Drug Designation for all three indications.[14] This designation provides significant development incentives, including tax credits for clinical testing and up to seven years of market exclusivity upon approval, for drugs intended to treat rare diseases affecting fewer than 200,000 people in the U.S..[14]
• Rare Pediatric Disease Designation: For DMD, Pamrevlumab also received Rare Pediatric Disease Designation.[17] This designation can lead to the awarding of a priority review voucher upon approval, which can be used to obtain an expedited six-month review for a future drug application and is a valuable, tradable asset.

This suite of designations underscored the FDA's belief in the potential of Pamrevlumab and provided FibroGen with significant regulatory and financial incentives to pursue its ambitious development plan.

5.2 European Medicines Agency (EMA) Engagement

The regulatory engagement in Europe mirrored the positive early reception in the U.S., particularly for the DMD indication.

• Orphan Designation: On December 16, 2019, the European Commission, acting on a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP), granted Pamrevlumab orphan designation (EU/3/19/2234) for the treatment of DMD.[48] The designation was supported by preliminary data suggesting the medicine might offer a significant benefit over existing therapies by improving heart and lung function in patients for whom no authorized treatments were available.[48]
• Paediatric Investigation Plan (PIP): In April 2022, the EMA agreed to a PIP for Pamrevlumab in DMD.[55] A PIP is a mandatory development plan that outlines the studies a company must conduct in children to support a marketing authorization application in the EU. The agreement on the PIP was a necessary step for any future submission and demonstrated that the proposed pediatric development plan was acceptable to the agency.[55]
• Designation Withdrawn: The most telling regulatory event in Europe was the withdrawal of the DMD orphan designation in October 2024.[48] This action was taken at the request of the sponsor and almost certainly came as a direct consequence of the failed LELANTOS Phase 3 trials.[48] With no evidence of efficacy, there was no basis to maintain the designation, and its withdrawal formally signaled the end of the drug's development prospects in Europe for this indication.

5.3 Strategic Synopsis and Program Termination

FibroGen's corporate strategy for Pamrevlumab was a high-risk, high-reward approach centered on the "pipeline-in-a-product" concept. By simultaneously advancing the drug into pivotal Phase 3 trials for three distinct, high-value indications, the company aimed to maximize the asset's potential and diversify against the risk of failure in any single area.[56] Investor presentations from 2022 prominently featured this parallel development strategy as a primary driver of the company's value, highlighting the significant commercial opportunities in IPF, LAPC, and DMD.[56]

However, this strategy had a critical vulnerability. While the target indications were clinically distinct, their success was entirely dependent on a single, unproven biological hypothesis: the efficacy of CTGF inhibition. This created a correlated risk profile where a failure in one indication would cast serious doubt on the others. This systemic risk materialized in a devastating cascade of failures over a 13-month period:

1. June 2023: The first domino fell with the announcement that the ZEPHYRUS-1 trial in IPF had failed.[17]
2. August 2023: The second failure followed quickly, with the negative results from the LELANTOS-2 trial in ambulatory DMD patients.[19]
3. July 2024: The final blow came with the simultaneous announcement that both the LAPIS and Precision Promise trials in pancreatic cancer had also failed to meet their primary endpoints of overall survival.[20]

The failure of the first trial in IPF immediately raised red flags about the validity of the drug's mechanism. The subsequent failures in DMD and pancreatic cancer confirmed that the lack of efficacy was not an indication-specific anomaly but a fundamental issue with the drug itself. The strategy that had once offered the promise of multiple blockbusters resulted in a systemic collapse of the entire program. Following the pancreatic cancer results, FibroGen had no choice but to concede the failure of the underlying hypothesis. The company announced the immediate termination of all Pamrevlumab research and development and initiated a major cost-reduction plan, including a 75% reduction in its U.S. workforce, to preserve capital and pivot to other assets in its pipeline.[20] This outcome demonstrates that a "pipeline-in-a-product" strategy is not truly diversified if all its components rely on the same unproven biological premise; failure, in such a case, becomes systemic and catastrophic.

6.0 Conclusive Analysis and Future Perspectives

The development and ultimate failure of Pamrevlumab provides a compelling and instructive case study in the complexities and risks of modern pharmaceutical research and development. Despite a strong scientific rationale, a favorable safety profile, and encouraging mid-stage clinical signals, the drug failed to deliver on its promise in late-stage trials, leading to the complete termination of a program that once held significant potential.

6.1 Synthesis of a High-Profile Clinical Failure

Pamrevlumab's failure can be attributed primarily to a flawed core therapeutic hypothesis. The premise that inhibiting a single, albeit central, molecular target like CTGF would be sufficient to meaningfully alter the course of complex diseases such as IPF, DMD, and pancreatic cancer proved to be incorrect. While preclinical and clinical evidence confirms that CTGF is an active participant in the pathophysiology of these conditions, its role is likely part of a highly redundant and interconnected network of signaling pathways. The clinical trial results suggest that blocking CTGF alone does not provide a potent enough intervention to overcome the other powerful drivers of disease progression. The consistency of this failure across three very different disease states—one idiopathic/autoimmune, one genetic, and one oncogenic—lends strong support to this conclusion.

A second critical factor in the Pamrevlumab story is the stark disconnect between the outcomes of Phase 2 and Phase 3 trials. In each of the three major indications, promising results from mid-stage studies were followed by definitive failures in large, well-controlled, confirmatory trials. This recurring pattern highlights the inherent limitations and risks of relying on surrogate endpoints (e.g., FVC decline in IPF, surgical resection rates in pancreatic cancer) and less rigorous study designs (e.g., open-label, use of historical controls in DMD) to make major investment and development decisions. The early positive signals were ultimately not reproducible under the stringent conditions of Phase 3 investigation, serving as a powerful reminder that statistical significance in a smaller, earlier trial does not guarantee clinical meaningfulness or replicability.

Finally, the fact that Pamrevlumab was consistently safe and well-tolerated is a crucial element of the analysis. The program was not derailed by unexpected toxicity or adverse events. This benign safety profile isolates the lack of efficacy as the sole reason for failure and reinforces the conclusion that the drug's mechanism of action, while engaging its target, did not translate into a tangible clinical benefit for patients.

6.2 Implications for the Field

The termination of the Pamrevlumab program has significant implications for the therapeutic areas it targeted and for the future development of anti-CTGF agents.

• For Anti-CTGF Therapies: The Pamrevlumab outcome casts a significant shadow over CTGF as a standalone therapeutic target. While the target is not invalidated as a contributor to disease, the results suggest that monotherapy targeting CTGF may be an insufficient strategy. Future research in this area may need to explore combination therapies, where CTGF inhibition is paired with agents that target other key pathways (such as upstream regulators like TGF-β), or focus on diseases where CTGF plays a more dominant, non-redundant role.
• For the Idiopathic Pulmonary Fibrosis (IPF) Treatment Landscape: The failure of Pamrevlumab, alongside other recent late-stage disappointments like the autotaxin inhibitor ziritaxestat, underscores the immense difficulty of developing new treatments for IPF.[4] The current standard of care, pirfenidone and nintedanib, can slow the rate of lung function decline but do not halt or reverse the fibrotic process, and many patients struggle with their side effects.[60] The urgent unmet need for more effective and better-tolerated therapies remains, with ongoing research exploring novel anti-fibrotic agents, immune modulators, and regenerative approaches.[61]
• For the Duchenne Muscular Dystrophy (DMD) Treatment Landscape: The DMD therapeutic landscape is in a period of rapid transformation, with the recent approval of the first gene therapy (Elevidys), next-generation steroids with improved side-effect profiles (Agamree), and novel non-steroidal agents (Duvyzat).[67] Pamrevlumab's failure removes a potential mutation-agnostic, anti-fibrotic treatment option from the late-stage pipeline. This outcome reinforces the focus of the field on primary therapeutic strategies such as dystrophin restoration (via gene therapy or exon-skipping) and modulation of inflammation and muscle health, which have now demonstrated clinical success.[69]
• For the Pancreatic Cancer Treatment Landscape: Pancreatic cancer remains one of the most challenging malignancies to treat, with chemotherapy regimens like FOLFIRINOX and gemcitabine/nab-paclitaxel forming the backbone of systemic therapy.[72] Targeted therapies and immunotherapies have shown only limited success in small, genetically defined patient subsets.[72] The failure of Pamrevlumab to improve overall survival by targeting the tumor stroma is a significant setback for this therapeutic approach and highlights the profound chemoresistance and biological complexity of the disease. The search for effective agents that can overcome the protective microenvironment of pancreatic tumors continues to be a major priority in oncology research.

Works cited

1. CAS 946415-13-0 Pamrevlumab - BOC Sciences, accessed August 26, 2025, https://www.bocsci.com/product/pamrevlumab-cas-946415-13-0-460358.html
2. Pamrevlumab Overview - Creative Biolabs, accessed August 26, 2025, https://www.creativebiolabs.net/pamrevlumab-overview.htm
3. Pamrevlumab - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Pamrevlumab
4. Pamrevlumab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/drug/3d4bc1894a494bfea7498513275cb5b6
5. Definition of pamrevlumab - NCI Drug Dictionary, accessed August 26, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pamrevlumab
6. Pamrevlumab (anti-CTGF) Datasheet - Selleck Chemicals, accessed August 26, 2025, https://www.selleckchem.com/datasheet/pamrevlumab-anti-ctgf-A2042-DataSheet.html
7. FG-3019 (Pamrevlumab) | Anti-Human CTGF Recombinant Antibody | MedChemExpress, accessed August 26, 2025, https://www.medchemexpress.com/fg-3019.html
8. pamrevlumab | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 26, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8928
9. Pamrevlumab (anti-CTGF) | Read Reviews & Product Use Citations - Selleck Chemicals, accessed August 26, 2025, https://www.selleckchem.com/products/pamrevlumab-anti-ctgf.html
10. Buy Pamrevlumab Biosimilar - Anti-CTGF/IGFBP-8 mAb - Research, accessed August 26, 2025, https://us.proteogenix.science/product/pamrevlumab-biosimilar-anti-ctgf-igfbp-8-mab-research-grade/
11. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/31575509/
12. The potential of pamrevlumab in diseases with underlying mechanisms of fibrotic processes and its prospects in ophthalmology - Pharmacia, accessed August 26, 2025, https://pharmacia.pensoft.net/article/144964/
13. Pamrevlumab Awarded Fast Track Development Status for Patients w/ Pancreatic C., accessed August 26, 2025, https://news.cancerconnect.com/pamrevlumab-awarded-fast-track-development-status-for-patients-w-pancreatic-c/
14. FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-granted-orphan-drug-designation-pamrevlumab-treatment
15. Pamrevlumab: A Breakthrough in Treating Fibrotic Diseases - Farbe Firma, accessed August 26, 2025, https://www.farbefirma.org/post/pamrevlumab-a-promising-treatment-for-fibrotic-diseases
16. Orphan Drug Designation Granted for Potential Duchenne Muscular Dystrophy Treatment, accessed August 26, 2025, https://patientworthy.com/2019/04/18/orphan-designation-duchenne-muscular-dystrophy-dmd-treatment/
17. FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-topline-results-phase-3-zephyrus-1-study
18. Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/37248912/
19. FibroGen's pamrevlumab disappointing results marks second failure ..., accessed August 26, 2025, https://www.clinicaltrialsarena.com/news/fibrogens-pamrevlumab-disappointing-results-marks-second-failure-in-a-row/
20. FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-topline-results-two-late-stage-pamrevlumab
21. Pamrevlumab Completed Phase 1 Trials for Diabetic Nephropathy / Diabetes Mellitus Treatment | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB14952/clinical_trials?conditions=DBCOND0027886%2CDBCOND0028920&phase=1&purpose=treatment&status=completed
22. Phase 1 study of anti-CTGF monoclonal antibody in patients with ..., accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/20522536/
23. FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-phase-2-study
24. Study Details | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | ClinicalTrials.gov, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT03955146
25. FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-completion-patient-enrollment-zephyrus-1
26. FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, accessed August 26, 2025, https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-topline-results-phase-3-zephyrus-1-study
27. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 ..., accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/38762797/
28. Research update: Results from ZEPHYRUS-1 - A Phase 3 Clinical Trial, accessed August 26, 2025, https://www.actionpf.org/news/research-update-results-from-zephyrus-a-phase-3-clinical-trial
29. FibroGen: Receives Fast Track Designation from FDA for Pamrevlumab, accessed August 26, 2025, https://defeatduchenne.ca/fibrogen-receives-fast-track-designation-fromfda-for-pamrevlumab/
30. FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial, accessed August 26, 2025, https://www.parentprojectmd.org/fibrogen-announces-first-patient-enrolled-in-pamrevlumab-phase-3-clinical-trial/
31. Pamrevlumab Terminated Phase 2 Trials for Duchenne Muscular Dystrophy (DMD) Treatment | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB14952/clinical_trials?conditions=DBCOND0040032&phase=2&purpose=treatment&status=terminated
32. Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (MISSION) - ClinicalTrials.gov, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT02606136
33. Pamrevlumab Granted Fast Track Designation by FDA for Locally Advanced Pancreatic Cancer - Targeted Oncology, accessed August 26, 2025, https://www.targetedonc.com/view/pamrevlumab-granted-fast-track-designation-by-fda-for-locally-advanced-pancreatic-cancer
34. FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-granted-fast-track-designation-us-fda-pamrevlumab
35. Pamrevlumab Fails to Provide OS Benefit in Pancreatic Cancer - OncLive, accessed August 26, 2025, https://www.onclive.com/view/pamrevlumab-fails-to-provide-os-benefit-in-pancreatic-cancer
36. FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer, accessed August 26, 2025, https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise
37. Sheet2 - Pharmacia, accessed August 26, 2025, https://pharmacia.pensoft.net/article/144964/download/excel/21/
38. Pamrevlumab Terminated Phase 1 Trials for Focal Segmental Glomerulosclerosis (FSGS) Treatment | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB14952/clinical_trials?conditions=DBCOND0038485&phase=1&purpose=treatment&status=terminated
39. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial - PMC - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11304118/
40. Pamrevlumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB14952
41. (PDF) FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/300081681_FG-3019_a_Human_Monoclonal_Antibody_Recognizing_Connective_Tissue_Growth_Factor_is_Subject_to_Target-Mediated_Drug_Disposition
42. FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-presents-latest-data-praise-phase-2b-study-0
43. Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | ClinicalTrials.gov, accessed August 26, 2025, https://clinicaltrials.gov/study/NCT01890265
44. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | ClinicalTrials.gov, accessed August 26, 2025, https://www.clinicaltrials.gov/study/NCT04419558
45. FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-receives-fast-track-designation-us-fda-pamrevlumab
46. Search Orphan Drug Designations and Approvals - FDA, accessed August 26, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=680319
47. FibroGen Receives U.S. FDA Orphan Drug Designation for Pamrevlumab for the Treatment of Duchenne - Parent Project Muscular Dystrophy (PPMD), accessed August 26, 2025, https://www.parentprojectmd.org/fibrogen-receives-orphan-drug-designation-from-the-u-s-fda-for-pamrevlumab-for-the-treatment-of-duchenne-muscular-dystrophy/
48. EU/3/19/2234 - orphan designation for treatment of Duchenne ..., accessed August 26, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2234
49. EU Clinical Trials Register, accessed August 26, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000698-26/FR
50. FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy, accessed August 26, 2025, https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-receives-fast-track-designation-us-fda-pamrevlumab-0
51. Fast Track Designation Granted to Idiopathic Pulmonary Fibrosis Treatment, Pamrevlumab, accessed August 26, 2025, https://www.hcplive.com/view/fast-track-designation-granted-idiopathic-pulmonary-fibrosis-treatment-pamrevlumab
52. Pamrevlumab - Orphanet, accessed August 26, 2025, https://www.orpha.net/en/drug/substance/512805?name=&mode=all®ion=
53. Fast Track | FDA, accessed August 26, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
54. FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-reports-fourth-quarter-and-full-year-2022-financial
55. European Medicines Agency decision P/0143/2022 of 13 April 2022 on the agreement of a paediatric investigation plan and on the g, accessed August 26, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0143-2022-ema-decision-13-april-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-pamrevlumab-emea-002979-pip01-21_en.pdf
56. FibroGen, Inc. Corporate Presentation, accessed August 26, 2025, https://investor.fibrogen.com/static-files/cfe34aa3-e31e-4148-bc0a-3ba53ff0eaba
57. FibroGen, Inc. Corporate Presentation, accessed August 26, 2025, https://fibrogen.gcs-web.com/static-files/ca6389a2-6710-4495-9311-9c6d549d1a4e
58. Corporate Presentation - FibroGen, Inc., accessed August 26, 2025, https://fibrogen.gcs-web.com/static-files/98150b05-bd2a-4940-b9b2-2d1230e105d7
59. FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update, accessed August 26, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-reports-second-quarter-2024-financial-results-and
60. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/32447983/
61. Advancing Idiopathic Pulmonary Fibrosis Treatments - PPD, accessed August 26, 2025, https://www.ppd.com/blog/advancing-idiopathic-pulmonary-fibrosis-treatments/
62. The changing treatment landscape in idiopathic pulmonary fibrosis - ERS Publications, accessed August 26, 2025, https://publications.ersnet.org/content/errev/24/135/65
63. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential, accessed August 26, 2025, https://publications.ersnet.org/content/errev/26/145/170071
64. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/37882943/
65. Report Highlights Advancements in 2024 Idiopathic Pulmonary Fibrosis Pipeline, accessed August 26, 2025, https://www.ajmc.com/view/report-highlights-advancements-in-2024-idiopathic-pulmonary-fibrosis-pipeline
66. Idiopathic pulmonary fibrosis: Current and future treatment - PMC - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9060042/
67. Duchenne Muscular Dystrophy Treatment In Transformation - Cure, accessed August 26, 2025, https://wewillcure.com/insights/rare-diseases/duchenne-muscular-dystrophy-treatment-in-transformation
68. Can emerging new treatments lead the way to cure Duchenne muscular dystrophy?, accessed August 26, 2025, https://www.labiotech.eu/in-depth/duchenne-muscular-dystrophy-treatment/
69. Latest Breakthroughs in Duchenne Muscular Dystrophy Research - TFS HealthScience, accessed August 26, 2025, https://tfscro.com/resources/advancements-in-duchenne-research-breakthroughs-and-promising-therapies/
70. The Evolving Treatment Landscape of DMD - NeurologyLive, accessed August 26, 2025, https://www.neurologylive.com/insights/the-evolving-treatment-landscape-of-dmd
71. The complex landscape of DMD mutations: moving towards personalized medicine - PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11002111/
72. Pancreatic Cancer: Review of the Current and Investigational Drug Landscape, accessed August 26, 2025, https://www.jhoponline.com/articles/pancreatic-cancer-review-of-the-current-and-investigational-drug-landscape